Printer Friendly

GenUs BioSystems Launches RNA Isolation Service.

Business Editors


-- Outsourced RNA Isolation Service To Assure Better Quality

Results, Streamline Gene Expression Profiling and Analysis For

Researchers --

GenUs BioSystems, a state-of-the-art bioarray service laboratory, today announced the launch of its RNA isolation services to researchers worldwide. RNA isolation is a critical early step in the generation of accurate and repeatable genomic data.

GenUs BioSystems' RNA isolation service was formed to compliment its overall outsourced gene expression data collection and analysis solution. Since tissue samples for genomic analysis are often small and irreplaceable, GenUs helps ensure maximum RNA recovery and quality gene expression data as a result.

"Today's advanced genomics tools are very good at highlighting bad samples," said Dr. Scott Magnuson, President of GenUs BioSystems. "Our new RNA isolation service offers researchers an effective alternative to performing this delicate step in the gene expression profiling process in their own lab."

Consistent with its "best available technology" philosophy, GenUs BioSystems combines the expertise of its staff with established and proven RNA isolation methods to take small amounts of cell and tissue samples and generate gene expression data upon which researchers can draw sound conclusions.

"Researchers simply want reliable answers to their scientific hypotheses. Our RNA isolation services coupled with our gene expression profiling and analysis services enable researchers to focus on the end result instead of the tools and training needed to achieve this result," said Dr. Magnuson.

About GenUs BioSystems, Inc.: GenUs BioSystems, Inc. is a service laboratory committed to using state-of-the-art techniques to conduct genomic experiments using bioarray technology in the emerging field of systems biology. Applications include genomic research, diagnostics, drug discovery, drug efficacy and toxicity studies, and pharmocogenetics. GenUs BioSystems provides a time saving and cost-effective alternative to performing technically challenging bioarray experiments in-house. For more information visit
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 5, 2003
Previous Article:Pittsburgh Law Firm of Alfred G. Yates Jr, P.C. Announces Class Action Lawsuit Against Federated Investors Mutual Funds on Behalf of Investors.
Next Article:LegalPlay Entertainment Inc. Announces Attendance at Skill Games Trade Association Meeting in Las Vegas.

Related Articles
Detection of North American West Nile Virus in Animal Tissue by a Reverse Transcription-Nested Polymerase Chain Reaction Assay.
Genetic characterization of the M RNA segment of Crimean Congo hemorrhagic fever virus strains, China. (Research).
First documentation of human crimean-congo hemorrhagic fever, Kenya. (Letters).
Genetic analysis of viruses associated with emergence of Rift Valley fever in Saudi Arabia and Yemen, 2000-01. (Research).
Real-time reverse transcription-polymerase chain reaction assay for SARS-associated coronavirus.
Laboratory diagnosis of SARS.
Yellow fever outbreak, Imatong, Southern Sudan.
Influenza a H5N1 detection.
Second human case of Cache Valley virus disease.
Rapid genome sequencing of RNA viruses.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters